Categories: News

OmniLife and ACTION Network Solidify Collaboration to Drive Innovation

LEXINGTON, Ky.–(BUSINESS WIRE)–#omnilife–OmniLife, a health technology communication and collaboration platform, has finalized its formal collaboration with the Advanced Cardiac Therapies Improving Outcomes Network, or ACTION. The organizations will work together to drive innovation around patient care and clinical decision making, specifically with the goal of improving outcomes for children with heart failure.

ACTION works to improve critical outcomes for all pediatric and congenital heart failure patients through its learning network approach, which allows the organization to make critical improvements faster across a collaborative system of providers, patients, families, researchers, and industry. As of October 2021, ACTION includes 55 pediatric hospitals in North America and seven additional sites globally.

ACTION will leverage OmniLife’s technology platform and provider network to create a collective intelligence system for secure and real-time clinical decision support and sharing of best practices across their national network.

“It is wonderful to work with companies that are aligned with our mission of improving care and outcomes for children with heart failure. Working with OmniLife will help us advance learning and accelerate innovative research,” commented Dr. Angie Lorts, co-executive director of ACTION and Director of Ventricular Assist Device at Cincinnati Children’s Hospital Medical Center.

“We are very excited to be working with ACTION to accelerate innovation with pediatric heart failure patients,” said Dalton Shaull, CEO of OmniLife. “I have a very personal connected purpose to the missions of OmniLife and ACTION, and we are thrilled that our work together will benefit children around the world.”

OmniLife has been leading efforts to improve communication, decision making, and secure information exchange between all stakeholders in the greater allotransplant ecosystem. Additionally, OmniLife is currently participating in a clinical trial funded by the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) which includes notable centers such as UPMC Children’s Hospital of Pittsburgh, Loma Linda University Transplant Institute, and Stanford Health Care Transplant Program.

About OmniLife:

OmniLife is a certified Benefit Corporation focused on maximizing the gift of life for purposes of transplantation and research. OmniLife is the only end-to-end communication system that is built specifically to create a more connected and collaborative allotransplant ecosystem. To learn more visit their website or contact info@getomnilife.com. https://www.getomnilife.com/about-us/

To learn more about OmniLife:

Interested in learning more about ACTION? Visit their website or contact them here.

actionlearningnetwork.org
info@actionlearningnetwork.org

Contacts

Dalton Shaull, dalton-shaull@getomnilife.com, 641-295-5367

Staff

Recent Posts

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…

1 second ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a…

5 seconds ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million…

11 seconds ago

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform…

19 seconds ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers…

26 seconds ago

Tilray Brands Reports Q2 2025 Financial Results

Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All…

28 seconds ago